AI Summary
This article discusses a new medication that has been approved by the US Food and Drug Administration as a biosimilar to aflibercept for treating diabetic macular edema. This suggests that the new medication has shown comparable effectiveness to the existing drug in treating this condition.
The new medication was one of two aflibercept biosimilars approved by the US Food and Drug Administration in May.
Medscape Medical News